This invention discloses a veterinary aluminum
hydroxide adjuvant for foot-and-mouth
disease (FMD) vaccines and its preparation method via aluminum
alkoxide hydrolysis. The
adjuvant is a
boehmite phase, and through innovative
processing, the
crystallinity and morphology are synergistically controlled, achieving a relative
crystallinity of 10%-25%. The primary particles are rod-shaped or needle-shaped, with an average
aspect ratio of 4:1 to 8:1. The preparation method includes: dissolving an aluminum
alkoxide compound, then subjecting it to a controlled
hydrolysis reaction at 50-80℃ and pH 4.5-6.5 under normal pressure for 36 hours, followed by aging at 425℃ for 2472 hours. The product is obtained after
solid-liquid separation, washing, and
drying. The obtained
adjuvant exhibits an adsorption rate of over 96% for FMD
virus inactivated
antigen within 1 hour, and a cumulative
antigen dissociation rate of less than 5% after 7 days at 37℃.
In vitro stimulation of macrophages to secrete IL-1β and TNF-α levels is more than 1.7 times that of commercially available aluminum
hydroxide adjuvants, significantly superior to traditional aluminum
hydroxide adjuvants, providing a new material for the preparation of highly effective FMD vaccines.